Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 3.22M -87.8% |
| Revenue (ttm) | 20.90M +45.2% |
| Net Income | -25.46M |
| EPS | -1.83 |
| Shares Out | 20.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 654,663 |
| Open | 0.1670 |
| Previous Close | 0.1632 |
| Day's Range | 0.1575 - 0.1670 |
| 52-Week Range | 0.1559 - 3.6100 |
| Beta | 6.00 |
| Analysts | Buy |
| Price Target | 2.12 (+1,224.17%) |
| Earnings Date | Aug 14, 2026 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its a... [Read more]
Financial Performance
In 2025, Vivos Therapeutics's revenue was $17.44 million, an increase of 16.05% compared to the previous year's $15.03 million. Losses were -$21.17 million, 90.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price target is $2.12, which is an increase of 1,224.17% from the latest price.
News
Vivos Therapeutics Announces Material Debt Reduction
LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and comm...
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on ...
Vivos Therapeutics, SPCVA to launch regional sleep testing and treatment center
Vivos Therapeutics (VVOS) announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, or SPCVA, to support the establishment and operation o...
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing a...
Vivos Therapeutics reports new patient referrals at Nevada Sleep & Airway
Vivos Therapeutics (VVOS) announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior…
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing a...
Vivos Therapeutics opens sleep testing, treatment facility in Nevada
Vivos Therapeutics (VVOS) announced the official Grand Opening of its latest state-of-the-art diagnostic, testing, and treatment location in Henderson, Nevada. The company expects this new full-servic...
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics Earnings Call Transcript: Q2 2026
Revenue rose 35% year-over-year in Q2 2026, driven by service growth from SCN and new treatment centers, while recurring revenue initiatives and clinical expansions are expected to accelerate growth into 2027. Cash constraints and Nasdaq compliance remain key risks.
Vivos Therapeutics Quarterly report: Q2 2026
Vivos Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Vivos Therapeutics Earnings release: Q2 2026
Vivos Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Au...
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing ...
Vivos Therapeutics expands strategic engagement with Greenway Health
Vivos Therapeutics (VVOS) announced an expanded strategic engagement with Greenway Health to deploy Greenway’s new AI-by-design Novare platform across Vivos’ growing clinical operations. Program imple...
Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1...
Vivos Therapeutics issued new U.S. patent for Vivos CARE devices
Vivos Therapeutics (VVOS) announced that the United States Patent and Trademark Office has issued US Patent No. 12,697,190 “Vibrational Oral Appliance with Mandibular Advancements”, a continuation of ...
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing a...
Vivos Therapeutics price target lowered to 75c from $1.75 at Alliance Global
Alliance Global lowered the firm’s price target on Vivos Therapeutics (VVOS) to 75c from $1.75 and keeps a Neutral rating on the shares after the company reported Q1 earnings on…
Vivos Therapeutics says Vida oral appliance improves insomnia in study
Vivos Therapeutics (VVOS) announced compelling clinical data showing that treatment with its FDA-cleared Vida oral appliance led to statistically significant improvement in insomnia severity in 100% o...
Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatmen...
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos and Streeterville Extend Timeframe of Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics intends to file registration statement for rights offering
Vivos Therapeutics (VVOS) announced that it intends to file a registration statement with the U.S. SEC for a proposed rights offering pursuant to which the company would distribute, as a…
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatmen...
Vivos Therapeutics enters pact with South Palm Cardiovascular Associates
Vivos Therapeutics (VVOS) announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates to support the formation and operation of AIM Florida, a physician-alig...
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients